CDTX
USDCidara Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$101.450
Максимум
$105.280
Минимум
$100.160
Объем
0.70M
Фундаментальные показатели компании
Рыночная капитализация
2.5B
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.84M
Биржа
NCM
Валюта
USD
52-недельный диапазон
Связанные новости
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $150 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics with a Buy and maintains $150 price target.
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
JP Morgan Initiates Coverage On Cidara Therapeutics with Overweight Rating, Announces Price Target of $200
JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics with a Overweight rating and announces Price Target of $200.
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.